Search the Newsreel

Valvoline (VVV) Appoints Katherine Fogertey And Scott Mezvinsky To Its Board

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Valvoline (NYSE:VVV) has appointed Katherine Fogertey and Scott Mezvinsky to its Board of Directors. The two executives bring experience in finance, restaurant industry transformation, and …

Dili raises $21.7M to bring AI compliance to the infrastructure boom

We already know that making AI work will mean bringing a lot of new data centers and power infrastructure online. But all those infrastructure projects may also need a bit of help from AI. On Thursday, a new AI compliance company called Dili that …

Palvella's CSO to present at FDA workshop on drug repurposing for rare diseases on August 5, 2026

Palvella Therapeutics' Chief Scientific Officer, Dr. Jeffrey Martini, will present at an FDA public workshop on August 5, 2026, to discuss drug repurposing for rare and chronic diseases. The workshop aims to explore methods for prioritizing FDA-approved drugs for new uses and address regulatory …

Valvoline Inc. Releases Fiscal 2025 Impact Report Highlighting Progress in People, Communities and Environmental Stewardship

Valvoline Inc. has released its Fiscal 2025 Impact Report, detailing significant progress in areas such as employee support, community engagement, and environmental efforts. Key achievements include raising a record $1.8 million for Children’s Miracle Network, investing over $1.4 million in service center upgrades, and …

Palvella Scientist Set to Discuss Reusing Approved Drugs at FDA

Palvella Therapeutics announced that its Chief Scientific Officer, Jeffrey Martini, Ph.D., will contribute to an upcoming FDA public workshop on drug repurposing on August 5, 2026. Dr. Martini will discuss evidence frameworks and regulatory approaches for advancing repurposed therapies, especially for rare diseases with …

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing

Palvella Therapeutics' Chief Scientific Officer, Dr. Jeff Martini, will present at an FDA public workshop on drug repurposing on August 5, 2026. The meeting aims to explore strategies for selecting and prioritizing FDA-approved drugs for new uses, accelerating access to therapies for unmet medical …

Alvotech (NASDAQ:ALVO) Given Consensus Rating of "Hold" by Brokerages

Alvotech (NASDAQ:ALVO) has received a consensus "Hold" rating from six brokerages, with an average 12-month price target of $7.60, significantly higher than its current share price of $3.53. Institutional investors like ProShare Advisors and Mirae Asset Global Investments have increased their stakes, while the …

Piper Sandler reiterates Valvoline stock rating on solid quarter outlook

Piper Sandler has reiterated an Overweight rating and a $44.00 price target for Valvoline (NYSE: VVV), predicting an 11% upside from its current trading price. The firm anticipates Valvoline will exceed estimates and raise guidance for its fiscal third quarter results, scheduled for August …

Palvella Therapeutics (PVLA) Expected to Post Quarterly Earnings on Tuesday

Alvotech Shares Rise After Wrapping FDA Facility Inspection

Alvotech's shares increased following the successful completion of a U.S. FDA facility inspection related to its a new biosimilar project, AVT02. The company received some observations but stated they are not expected to impact the timeline for its Humira biosimilar. This marks a significant …

VVV|Valvoline Inc|Price:39.296|Chg%:-0.354

This article provides a comprehensive stock analysis of Valvoline Inc (VVV) from TradingKey. It highlights the company's stable fundamentals, high growth potential, and fair valuation within the Personal & Household Products & Services industry. The analysis includes key insights, score breakdown, strengths like revenue …

Autoliv Inc (ALV) Financial Health: Profitability & Balance Sheet Analysis

Autoliv Inc (ALV) currently holds a financial score of 8.04, ranking 15th out of 69 in the Automobiles & Auto Parts industry, indicating stable financial health and average operating efficiency. The company reported a quarterly revenue of $2.80 billion, a 3.28% year-over-year increase, and …

BlackRock (PVLA holder) discloses 5.7% beneficial stake in Palvella Therapeutics

BlackRock, Inc. has filed a Schedule 13G, disclosing a 5.7% beneficial ownership stake in Palvella Therapeutics, Inc. (PVLA) as of June 30, 2026. This ownership represents 812,953 shares of common stock, with BlackRock holding sole voting power over 796,317 shares and sole dispositive power …

PVLA|Palvella Therapeutics Inc|Price:142.540|Chg%:-0.300

This article provides a comprehensive stock analysis of Palvella Therapeutics Inc (PVLA), highlighting its strong fundamentals, high growth potential, and "Buy" ratings from analysts with a target price of $229.00. The company, a clinical-stage biopharmaceutical firm, is developing therapies for rare genetic skin diseases, …

ALTI|AlTi Global, Inc|Price:3.827|Chg%:+0.227

AlTi Global, Inc. is an independent global wealth manager offering fiduciary capabilities, alternative investment strategies, and advisory services. The company operates through its Wealth & Capital Solutions segment, providing comprehensive wealth management and OCIO services, and an International Real Estate segment focused on co-investments …

Valvoline Inc. (VVV) Stock Forecasts

Argus has raised its target price for Valvoline Inc. (VVV) to $42.00, up from its previous target. Valvoline, a consumer cyclical company, produces and markets automotive maintenance products, primarily lubricants, to various customers. The current stock price for VVV is $39.65.

Is Valvoline’s (VVV) Board Adding Consumer Veterans Altering The Investment Case For Valvoline?

Valvoline Inc. has enhanced its Board of Directors by appointing Katherine Fogertey (former Shake Shack CFO) and Scott Mezvinsky (CEO of Yum! Brands’ KFC division), signaling a stronger focus on operational discipline, brand growth, and board oversight. While these additions bring significant consumer and …

Autoliv (ALV) Balances Softer Earnings With Major Buyback Is Its Capital Allocation Evolving?

Autoliv (ALV) reported softer Q2 and half-year 2026 earnings but completed a significant US$450 million share repurchase, retiring nearly 5% of its shares. This buyback meaningfully alters per-share metrics amidst sales growth but weaker profitability, prompting investors to assess whether the capital allocation strategy …

US FDA Closes Inspection of Alvotech's Manufacturing Facility in Iceland

Alvotech has announced the successful conclusion of a U.S. FDA inspection of its manufacturing facility in Reykjavik, Iceland, with no Form 483s issued. This positive outcome is a significant step for the company, as it addresses previous issues that had prevented the approval of …

Valvoline Q3 Same-Store Sales Expected to Beat Estimates, RBC Says

RBC analysts predict Valvoline's Q3 same-store sales will surpass estimates. The article highlights recent company news, analyst ratings, and an overview of Valvoline's business, which focuses on automotive preventive maintenance services through its franchised and company-operated service centers.

Alvotech (NASDAQ:ALVO) Shares Up 13.5% - Here's What Happened

Alvotech (NASDAQ:ALVO) saw its shares climb 13.5% in mid-day trading but with significantly reduced volume. Analyst sentiment is mixed, with an average "Hold" rating and a target price of $7.60, as the company continues to report negative profitability despite $105.9 million in quarterly revenue. …

Alvotech Marks Key Milestone As FDA Closes Inspection Of Reykjavik Facility; Stock Up

(RTTNews) - Alvotech (ALVO), a biotechnology company focused on developing and manufacturing biosimilar medicines, announced that the U.S. FDA has successfully closed its inspection of the company's manufacturing facility in Reykjavik, Iceland, conducted in May 2026. The FDA classified the site as Voluntary Action …

FDA closes Alvotech (NASDAQ: ALVO) Iceland plant inspection with VAI status

Alvotech (NASDAQ: ALVO) announced that the U.S. FDA has closed its May 2026 inspection of its Reykjavik, Iceland manufacturing facility with a Voluntary Action Indicated (VAI) classification. The company views this as a significant milestone, reflecting enhanced quality systems and manufacturing operations. Alvotech continues …

Alvotech clears FDA inspection of Iceland manufacturing site, advancing biosimilar drug approvals.

Alvotech announced the successful closure of an FDA inspection at its manufacturing facility in Reykjavik, Iceland, which was classified as Voluntary Action Indicated (VAI). This clearance is a crucial step for Alvotech, allowing the company to advance its biosimilar drug pipeline. The company is …

Alvotech works toward FDA approval for three biosimilar applications

Alvotech announced that the FDA has closed its May 2026 inspection of the company's Reykjavik manufacturing facility with a Voluntary Action Indicated (VAI) classification, indicating concerns that the firm is asked to address voluntarily. This positive outcome reflects the company's efforts to strengthen quality …

Alvotech announces successful closure of FDA inspection of manufacturing facility

Alvotech announced the successful closure of an FDA inspection of its Reykjavik, Iceland manufacturing facility, with the FDA classifying the site as Voluntary Action Indicated (VAI). This is a significant milestone for Alvotech, demonstrating strengthened quality systems and manufacturing operations. The company is confident …

Valvoline (VVV) to Release Quarterly Earnings on Wednesday

Valvoline's Fast Growth Opens The Path To Slick Upside

Palvella Therapeutics Inc (PVLA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Palvella Therapeutics Inc (PVLA), noting its current valuation score and P/E ratio. It highlights that the company ranks 41 out of 385 in the Biotechnology & Medical Research industry. The report also indicates that relevant data for …

Valvoline (NYSE:VVV) - Stock Analysis

This article provides a detailed stock analysis of Valvoline (NYSE:VVV), covering its market performance, financial health, growth prospects, and recent news. Key highlights include an analyst consensus target indicating the stock is undervalued, significant earnings growth forecasts, and recent executive appointments. The analysis also …

Palvella sets Aug. 4 update on rare skin disease therapies

Palvella Therapeutics (Nasdaq: PVLA) will report its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Management will host an investor conference call and webcast at 8:30 a.m. ET that day to discuss the results and provide a corporate update. …

Valvoline Inc (VVV) Q2 2023 Earnings Report - Results, Call & Slides

This article provides details on Valvoline Inc's (VVV) Q2 2023 earnings report. The company beat EPS expectations at $0.23 against a consensus of $0.22, but missed revenue forecasts, reporting $344.50M against an expected $347.48M. The report also includes historical earnings data and future estimated …

Valvoline FY25 Impact Report Highlights Progress

Valvoline Inc. has released its Fiscal Year 2025 Impact Report, detailing significant progress in community giving, sustainability, workforce growth, and operational investments. Key achievements include raising a record $1.8 million for Children’s Miracle Network and investing over $1.4 million in energy upgrades. The report …

Palvella Therapeutics to report Q2 2026 results on August 4

Palvella Therapeutics will report its Q2 2026 financial results on August 4, 2026, before market open, followed by an investor conference call at 8:30 a.m. ET. The company will discuss its financial performance and provide a corporate update, focusing on its QTORIN™ platform for …

Palvella Therapeutics Inc (PVLA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown of Palvella Therapeutics Inc (PVLA), stating that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company. It notes PVLA's current stock price, market cap, and P/E TTM. The content indicates …

Autoliv Inc (ALV) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Autoliv Inc (ALV), focusing on its current price momentum, support and resistance levels, and key technical indicators. It details the performance of various indicators like MACD, RSI, and moving averages, offering insights into potential trading signals. The …